RARA and breast cancer: More recently, retinoic acid (RA) and other RAR agonists were found to be growth inhibitory for cancer cell lines in vitro [2-7], in carcinogen-induced rodent mammary cancer models, [8-10] and in xenograft models of human cancer cell [11-13].